The Anti-Cancer Effect of A3 Adenosine Receptor Agonists: A Novel, Targeted Therapy

Publisher： Bentham Science Publishers

E-ISSN： 1875-6115|7|4|298-303

ISSN： 1871-5222

Source： Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Immunology, Endocrine and Metabolic Agents), Vol.7, Iss.4, 2007-08, pp. : 298-303

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Agonists to the A3 adenosine receptor induce G-CSF production via NF- B activation - A new class of myeloprotective agents

By Bar-Yehuda S.   Madi L.   Barak D.   Mittelman M.   Ardon E.   Ochaion A.   Cohn S.   Fishman P.  

Experimental Hematology, Vol. 30, Iss. 12, 2002-12 ,pp. : 1390-1398

Elsevier

Access to resources Recommend Favorite

Targeting Endothelial Progenitor Cells in Cancer as a Novel Biomarker and Anti-Angiogenic Therapy

By  

Current Stem Cell Research & Therapy, Vol. 10, Iss. 2, 2015-03 ,pp. : 181-187

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting Endothelial Progenitor Cells in Cancer as a Novel Biomarker and Anti-Angiogenic Therapy

By  

Current Stem Cell Research & Therapy, Vol. 10, Iss. 2, 2015-01 ,pp. : 181-187

Bentham Science Publishers

Access to resources Recommend Favorite

Ovarian Cancer - Angiogenesis and Targeted Therapy

By  

Current Angiogenesis, Vol. 3, Iss. 4, 2014-01 ,pp. : 215-230

Bentham Science Publishers

Access to resources Recommend Favorite

Guidelines on obtaining consent for systemic anti-cancer therapy in adults

By Treleaven J.   Gadd E.   Cullis J.   Favre J.   McLeod A.   Meller S.   Milligan D.   Neilson R.   Quinn B.   Webb A.   Wimperis J.  

Hematology, Vol. 17, Iss. 5, 2012-09 ,pp. : 249-254

Maney Publishing

Access to resources Recommend Favorite